BioSpace News Archive

Labcorp® (NYSE: LH), a leading global life sciences company, today announced an expansion of its automated clinical trial kit production line in Mechelen, Belgium.

Hansa Biopharma AB, (Hansa), (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announces that the Company has entered into an agreement with U.S.-based NovaQuest Capital Management, securing $70 million in non-dilutive financing.

LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its second quarter 2022 financial results on Thursday, July 28, 2022, after the market close.

Aeterna Zentaris Inc. announced that the Company has filed articles of amendment, to effect the previously announced share consolidation of its issued and outstanding common shares on the basis of one post-Consolidation Common Share for every twenty-five pre-Consolidation Common Shares.

The Foundation for Sarcoidosis Research (FSR) hosted a virtual Patient Listening Session on Pulmonary Sarcoidosis with the US Food and Drug Administration (FDA).

AnPac Bio-Medical Science Co., Ltd., a biotechnology company with operations in the United States and China focused on early cancer screening and detection, announced that the Company’s Members approved Written Resolutions of a Majority of the Members on July 14, 2022 addressing the removal of directors and officers, re-designation of officers, and change of members of the committees.

Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Opzelura™ (ruxolitinib) cream 1.5% for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older.

Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a life sciences company commercializing the first next generation single molecule protein sequencing, today announced that it will report financial results for the second quarter 2022 after market close on Monday, August 8, 2022.

Celcuity Inc. announced that the U.S. Food and Drug Administration has granted gedatolisib Breakthrough Therapy designation for the treatment of patients with HR+/HER2- metastatic breast cancer whose disease progressed during treatment with a CDK4/6 therapy and a non-steroidal aromatase inhibitor.

Innovent Biologics, Inc. (Innovent) (HKEX: 01801), announces that the primary endpoint was met in a multi-center, randomized, double-blind, placebo and dulaglutide-controlled phase 2 study of mazdutide (R&D code: IBI362), a glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR) dual agonist, in Chinese patients with type 2 diabetes.